Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Anti-epileptic drug may reduce migraine aura (opens in a new tab)

medicalxpress.com · 2026-09-25

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 2 supported
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Two of four claims match the study. This overall rating is based only on the claims we could check. Two claims the study doesn't address.

  • 2 supported
  • 2 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

4 claims in this story

Showing all 4 claimsChoose a verdict to focus the list.

Claim 1 of 4Not coveredThe article says the study is retrospective and lacks a control group, so the results need confirmation in a controlled study; the researchers are now proceeding with a national randomized, double-blind, placebo-controlled trial of lamotrigine.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that the study was retrospective/observational, uncontrolled, and that controlled trials are needed or warranted. However, the specific assertion that the researchers are now proceeding with a national, randomized, double-blind, placebo-controlled trial is not present in the supplied abstract-depth paper profile, so that part cannot be verified at this depth.

1

Study evidence

Lamotrigine initiation was associated with a large reduction in monthly aura days: mean MADs decreased from 6.9 ± 7.5 to 1.4 ± 3.7 days/month (79.7% mean reduction) with p < 0.001; 85.2% of patients met the predefined response threshold (≥50% reduction).Mean MADs reduced from 6.9 ± 7.5 to 1.4 ± 3.7 (79.7% mean reduction); p < 0.001; response rate 85.2% (≥50% reduction).

“A retrospective observational study was conducted at a neurology clinic in Lund, Sweden, including 81 patients treated between 2014 and 2022.”
Claim 2 of 4Not coveredThe article frames lamotrigine as an anti-epileptic drug approved for epilepsy and bipolar disorder, not migraine, and says it could eventually become a relatively inexpensive treatment option for aura-dominant migraine if confirmed.View evidenceHide evidence

Why this verdict

The abstract-level profile supports only the general idea that lamotrigine is being evaluated as a prophylactic/preventive option for burdensome migraine aura and warrants controlled evaluation. It does not verify the regulatory framing that lamotrigine is approved for epilepsy and bipolar disorder but not migraine, nor the cost claim that it could become a relatively inexpensive option, nor the stronger statement that patients currently have no treatment for the aura itself.

1

Study evidence

Lamotrigine initiation was associated with a large reduction in monthly aura days: mean MADs decreased from 6.9 ± 7.5 to 1.4 ± 3.7 days/month (79.7% mean reduction) with p < 0.001; 85.2% of patients met the predefined response threshold (≥50% reduction).Mean MADs reduced from 6.9 ± 7.5 to 1.4 ± 3.7 (79.7% mean reduction); p < 0.001; response rate 85.2% (≥50% reduction).

“A retrospective observational study was conducted at a neurology clinic in Lund, Sweden, including 81 patients treated between 2014 and 2022.”
Claim 3 of 4SupportedA new study by researchers at Lund University found that 85% of patients with aura-dominant migraine experienced a reduction in monthly aura days by at least half following treatment with the anti-epileptic drug lamotrigine.View evidenceHide evidence

As stated85% with at least 50% reduction in monthly aura days

Why this verdict

The abstract-level paper profile supports the core quantitative claim: in a retrospective Lund clinical cohort of 81 patients with burdensome/frequent or severe migraine aura treated with lamotrigine, the reported overall response rate for ≥50% reduction in monthly aura days was 85.2%. The wording is framed as a post-treatment/pre–post finding rather than a causal trial result, so it is not overstated on that basis, though the abstract evidence is observational and uncontrolled.

1

Study evidence

Lamotrigine initiation was associated with a large reduction in monthly aura days: mean MADs decreased from 6.9 ± 7.5 to 1.4 ± 3.7 days/month (79.7% mean reduction) with p < 0.001; 85.2% of patients met the predefined response threshold (≥50% reduction).Mean MADs reduced from 6.9 ± 7.5 to 1.4 ± 3.7 (79.7% mean reduction); p < 0.001; response rate 85.2% (≥50% reduction).

“A retrospective observational study was conducted at a neurology clinic in Lund, Sweden, including 81 patients treated between 2014 and 2022.”
Claim 4 of 4SupportedIn the study of 81 patients with frequent or particularly troublesome migraine aura, the average number of aura days fell from 6.9 to 1.4 days per month, a reduction of around 80%.View evidenceHide evidence

As statedfrom 6.9 to 1.4 days per month; around 80% reduction

Why this verdict

This matches the abstract-level result: mean monthly aura days decreased from 6.9 ± 7.5 to 1.4 ± 3.7 after lamotrigine initiation, reported as a 79.7% mean reduction with p < 0.001 in the 81-patient retrospective cohort.

1

Study evidence

Lamotrigine initiation was associated with a large reduction in monthly aura days: mean MADs decreased from 6.9 ± 7.5 to 1.4 ± 3.7 days/month (79.7% mean reduction) with p < 0.001; 85.2% of patients met the predefined response threshold (≥50% reduction).Mean MADs reduced from 6.9 ± 7.5 to 1.4 ± 3.7 (79.7% mean reduction); p < 0.001; response rate 85.2% (≥50% reduction).

“A retrospective observational study was conducted at a neurology clinic in Lund, Sweden, including 81 patients treated between 2014 and 2022.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Causal inference limitations: because the study was uncontrolled and pre–post, placebo effects, regression to the mean, confounding, selection bias, and reporting bias cannot be excluded.

    The story mentions the retrospective design and lack of control group, which are important caveats, but the supplied caveats do not mention several interpretation-changing limitations identified in the profile, including regression to the mean/placebo effects, confounding, and selection/reporting biases.

    From Retrospective observational cohort (single-center)

  • Generalizability limitation: clinic cohort of patients with burdensome aura from a single Lund neurology clinic may not generalize to broader migraine populations.

    The story describes the cohort as patients with frequent or troublesome aura, but it does not identify the single-center clinic cohort and potential selection/generalizability limits as caveats.

    From Retrospective observational cohort (single-center)

  • Secondary safety/tolerability contribution: mean lamotrigine dose was 149.6 mg; 29 patients had adverse events, most commonly skin changes; 5 discontinued because of adverse events.

    The paper profile includes dosing and adverse-event/tolerability reporting as a secondary contribution. The story presentation provided here does not report the adverse-event rate, common skin changes, or discontinuations, even though these are material for evaluating lamotrigine as a potential treatment option.

    From Retrospective observational cohort

  • Safety-reporting limitations: adverse-event ascertainment came from retrospective clinical records with limited detail on severity, timing, standardized assessment, and comparator safety rates.

    Because the story omits the safety findings, it also omits the limitations on interpreting those safety findings, including lack of standardized AE assessment and no comparator group for harms.

    From Retrospective observational cohort

2 things the story did carry across
  • Primary study design: retrospective, single-center observational cohort with pre–post comparison and no control/comparator group.
  • Primary efficacy finding: lamotrigine initiation was associated with a large reduction in monthly aura days, with mean MADs falling from 6.9 to 1.4 and an 85.2% ≥50% response rate.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoAssess whether lamotrigine prophylaxis is associated with a clinically meaningful reduction in migraine aura frequency (monthly aura days) in a real-world cohort with burdensome aura.Retrospective observational cohort (single-center)Expand

In plain English

Retrospective, single-center observational cohort (n=81) of patients with burdensome migraine aura treated with lamotrigine (LTG) at a neurology clinic in Lund, Sweden (2014–2022). Primary outcome was the proportion achieving ≥50% reduction in monthly aura days (MADs) after LTG initiation. Mean MADs decreased from 6.9 ± 7.5 to 1.4 ± 3.7 days/month (79.7% mean reduction, p < 0.001); the reported overall response rate (≥50% reduction) was 85.2%. Mean LTG dose was 149.6 ± 70.5 mg. Twenty-nine patients experienced adverse events (most commonly skin changes) and 5 discontinued treatment because of adverse events. Authors conclude LTG is associated with reduced aura frequency and was generally tolerated in this clinical cohort, and recommend further evaluation in controlled trials.

Key findings

  • Lamotrigine initiation was associated with a large reduction in monthly aura days: mean MADs decreased from 6.9 ± 7.5 to 1.4 ± 3.7 days/month (79.7% mean reduction) with p < 0.001; 85.2% of patients met the predefined response threshold (≥50% reduction).Mean MADs reduced from 6.9 ± 7.5 to 1.4 ± 3.7 (79.7% mean reduction); p < 0.001; response rate 85.2% (≥50% reduction).
  • Adverse events were reported in 29 patients (most commonly skin changes); 5 patients discontinued LTG because of adverse events.
“A retrospective observational study was conducted at a neurology clinic in Lund, Sweden, including 81 patients treated between 2014 and 2022.”
What this piece can’t prove
  • Retrospective, observational, single-center design without a control or comparator group limits causal inference.
  • Abstract lacks detail on follow-up duration, methods of MAD ascertainment (e.g., diary vs recall), and handling of missing data.
  • Potential selection bias (clinic cohort of patients with burdensome aura) may limit generalizability to broader migraine populations.
  • Possible regression to the mean or placebo effects cannot be excluded in a pre–post design.

1 further detail could not be confirmed from the summary.

2human in vivoDescribe lamotrigine dosing patterns, tolerability, and adverse events (including discontinuations) during long-term management in this cohort.Retrospective observational cohortExpand

In plain English

In this retrospective clinical cohort of 81 patients treated with lamotrigine (LTG) for burdensome migraine aura, the abstract reports a mean LTG dose of 149.6 mg (±70.5). Safety reporting from clinic records identified 29 patients with adverse events (most commonly described as skin changes) and 5 patients who discontinued LTG because of adverse events.

Key findings

  • Mean lamotrigine dose during treatment was 149.6 mg (±70.5); 29 of 81 patients experienced adverse events (most commonly skin changes), and 5 patients discontinued treatment because of adverse events.Mean dose 149.6 mg ± 70.5; 29 patients with AEs; 5 discontinuations due to AEs
“The average dose of LTG was 149.6 mg ± 70.5.”
What this piece can’t prove
  • Adverse event ascertainment relied on clinical record review; the abstract does not report severity grades, onset timing, or standardized AE assessment procedures.

3 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

Candidate

Lamotrigine in the prophylaxis of migraine: comparison of effectiveness in migraine with and without aura in patients with depression and anxiety symptoms

Comprehensive Medicine · 2023 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.